RIEMSER expands to Spain with acquisition of multichannel commercialization and distribution specialist Zaltanpharma

Berlin, October 2, 2019 – Riemser Pharma GmbH (RIEMSER), a specialty pharmaceutical company operating throughout Europe, today announced that it has acquired Zaltanpharma (Zaltan), a leading company for multichannel commercialization and distribution of pharmaceuticals based in Madrid (Spain), from Icon Group, an international group of companies operating in the field of services and commercial consulting in the healthcare industry. Zaltan’s focus is on the therapeutic areas of oncology, pain medicine and urology. Its excellent distribution relationships with clinicians perfectly match RIEMSER’s profile and distribution focus, allowing the German pharma firm to foster its internationalization.

Zaltan was founded in 2017 and with its currently around 20 employees offers sales force and marketing know-how to pharmaceutical companies. Its expert sales team has particular expertise in marketing specialty pharmaceuticals to hospital physicians. Going forward, Zaltan will be fully integrated into RIEMSER and operate under the name of RIEMSER Iberia s.l. RIEMSER Iberia will continue to render its services to existing customers and will provide its expertise further to the parent company in order to support it in expanding its distribution network and launching further products on the Spanish market.

The acquisition of Zaltan marks the next step in implementing RIEMSER’s internationalization strategy. In the years 2014 and 2015, RIEMSER has acquired the subsidiaries Keocyt based in France and Intrapharm based in England. Through the acquisition of Zaltan, Spain becomes the fourth core market for RIEMSER, who is licensing and distributing specialty pharmaceuticals internationally. In 2018, RIEMSER introduced Triamcinolone Hexacetonide in Canada and has been granted the distribution rights for Jylamvo in the UK. In the same year, the company obtained exclusive development and marketing rights for Prialt in Europe from Japanese pharma company Eisai. In 2019 RIEMSER completed a new EU approval for Zanosar in eleven European countries through its subsidiary Keocyt.

Konstantin von Alvensleben, CEO of RIEMSER, said: “We are proud to take the next step in expanding our international footprint. The acquisition of Zaltan enables us to strengthen our presence in a market that is particularly attractive due to its growth potential. The know-how and local expertise of the Zaltan team will be essential to succeed in this market and I am very happy that our companies not only match on business terms, but also share the same philosophy, which is to alleviate suffering and improve quality of life through innovative pharmaceuticals.”

Enrique Remezal, CEO of Zaltanpharma, added: “RIEMSER is a relevant player in the European and international specialty pharma landscape and has achieved remarkable success by consistently pursuing its very focused strategy in recent years. We are proud to become part of this success story and are very much looking forward to working with our new colleagues at RIEMSER.”

 

About Riemser Pharma GmbH

Riemser Pharma GmbH was established in 1992 and emerged from the Friedrich Löffler Institute on Riems Island (Greifswald). RIEMSER has been in business for more than 25 years, during which it has evolved from a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine.

RIEMSER sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 took place in the last three years, are a testament to the special expertise of RIEMSER for the approval and opening of new markets for pharmaceutical products.

The product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis. Medicinal products and food supplements complement the portfolio.

Besides its international group headquarters in Berlin, the company has three locations in Germany. In 2014 and 2015 RIEMSER acquired the subsidiaries Keocyt based in France and Intrapharm based in England. In addition, it has established an international distribution network. RIEMSER is a portfolio company of Ardian, one of the world’s leading private investment companies.

For more information, please visit www.riemser.com

 

About Zaltanpharma

Zaltanpharma is a leading company for multichannel commercialization and distribution of pharmaceuticals based in Madrid (Spain). The company is a service provider offering sales force and marketing know-how to pharmaceutical companies. Its expert sales team has particular expertise in marketing and distributing specialty pharmaceuticals, among others in the therapeutic areas of oncology, pain medicine and urology, to hospital physicians. Zaltanpharma was founded in 2017 and currently employs around 20 people.

 

Press Contact
Riemser Pharma GmbH
Dr. Marlies Michaelis
michaelis[at]riemser[dot]com
Tel: +49 30 338427- 405